Benefits
Butyrate production in the gut
This strain makes butyrate, a short chain fatty acid that the cells lining the colon use for energy. That sets it apart from lactic acid probiotics such as Lactobacillus and Bifidobacterium. This is laboratory biology: none of the studies cited on this page measured butyrate levels or gut health in healthy adults.
Antibiotic-associated diarrhea prevention
One study from 2003, in children taking antibiotics, reported fewer cases of antibiotic-associated diarrhea (PMID 12654076). That is the only human study of this use cited here, it is more than twenty years old, and it was not done in adults. The spore form is expected to survive stomach acid and concurrent antibiotics better than typical probiotics.
Irritable bowel syndrome: results not yet published
No published trial supports this. One 8 week trial in people with diarrhea-predominant irritable bowel syndrome (NCT06676514) has finished, but its results have not been published, so there is nothing yet to report about symptoms or stool consistency. Ongoing bowel symptoms should be assessed by a doctor rather than self-treated.
What the cancer trials actually showed (phase 1 studies in patients on prescription cancer drugs)
Two small phase 1 trials, 30 people each, gave CBM588 to patients with advanced kidney cancer who were already receiving prescription cancer drugs (nivolumab with ipilimumab in 2022, cabozantinib with nivolumab in 2024). Both trials missed their main goal: there was no significant change in Bifidobacterium levels or in overall gut bacteria diversity. The differences in tumor response were secondary findings, and in the 2022 trial that difference was not statistically significant (58% versus 20%, P=0.06). The authors describe the results as a preliminary signal needing confirmation. A separate lung cancer study was observational, so it shows an association, not an effect. None of this shows that a probiotic treats cancer or improves survival, and nobody with cancer should start or stop anything without their oncologist.
Inflammatory bowel disease: no evidence cited here
No trial in inflammatory bowel disease is cited on this page, so there is nothing here to back this up. Inflammatory bowel disease is a serious medical condition that needs care from a doctor, and a probiotic is not a substitute for prescribed treatment.
Gut barrier function support
In laboratory and animal work, butyrate helps tighten the junctions between the cells lining the colon. That is the proposed reason people are interested in this strain. Gut permeability and inflammation were not measured in any of the human studies cited on this page.
Decades-long Japanese safety record
This strain has been used in Japan since the 1960s, where MIYA-BM is a prescription product rather than a supplement. Long real-world use is reassuring, but it is not the same as a controlled long-term safety study, and no such study is cited on this page.
Mechanism of action
Butyrate production (distinguishing from Lactobacillus/Bifidobacterium)
C. butyricum is a butyrate producer — distinct from the lactic-acid-producing Lactobacillus and Bifidobacterium probiotics. Butyrate is the primary energy source for colonocytes (60-70% of their energy), and in laboratory studies it affects enzymes involved in inflammation. This is the proposed explanation for why the strain might matter, not a result demonstrated in the human studies cited here.
Spore formation with heat and acid resistance
Like other Clostridium species, C. butyricum forms endospores resistant to gastric acid, bile, and heat — enabling reliable transit through the upper GI tract to the colon where it germinates and exerts effects.
C. difficile inhibition (laboratory findings only)
In laboratory work, CBM 588 lowered succinate (a nutrient C. difficile uses to grow), acted alongside the antibiotic fidaxomicin, and reduced toxin activity in test tubes. None of this has been shown in a human trial cited on this page, and C. difficile infection is a serious condition that needs prompt medical care and prescription antibiotics.
Mucin layer protection and production
In animal and laboratory studies, CBM 588 supported the mucus layer that separates gut bacteria from the gut wall. A healthy mucus layer is thought to help keep bacteria where they belong. This was not measured in any of the human studies cited on this page.
TNF-α downregulation and IgA upregulation
In laboratory and animal work, CBM 588 lowered TNF-alpha (an inflammatory signal) in immune cells of the gut wall and raised production of IgA, an antibody that coats the gut lining. These are preclinical observations. They have not been shown to make people more resistant to infection, and no human study cited here measured immune outcomes.
Cross-feeding support of beneficial commensals
In laboratory studies, substances made by CBM 588, including butyrate, helped other gut bacteria such as Bifidobacterium and Lactobacillus grow. Worth knowing: the two cancer trials cited on this page did measure Bifidobacterium in people, and found no significant increase. That was the main goal of both trials, and both missed it.
Cancer-related laboratory pathways (no human results)
In the laboratory, butyrate affects several cell pathways that researchers think might matter in bowel cancer. That reasoning is why a trial on polyp recurrence was started. The trial is still enrolling and has produced no results. There is no evidence that this probiotic prevents or treats any cancer, and it is not a substitute for colonoscopy or medical care.
Clinical trials
Nature Scientific, doi:10.1038/s41598-021-94572-z.
Clinical population described in trial publication.
Nature Scientific, doi:10.1038/s41598-021-94572-z. In laboratory work, CBM 588 improved resistance to C. difficile through changes in metabolism and immune signaling: it enhanced the antibacterial activity of fidaxomicin in the lab, negatively modulated gut succinate (substrate for C. difficile), downregulated colon-resident macrophage TNF-α, upregulated IgA through IL-17A CD4+ T cells and plasma B cells, and strengthened the gut lining. This was a laboratory study, not a human trial, and it is not among the four PubMed references listed on this page. It does not show that taking this probiotic prevents C. difficile infection in people.
Liaquat University Pakistan, completed.
Clinical population described in trial publication.
Liaquat University Pakistan, completed. This registered trial compared Butirrisan, 3 tablets a day for 8 weeks, against standard care (the prescription drug trimebutine plus a lactose free, low residue diet) in people with diarrhea-predominant irritable bowel syndrome. No results have been published, so nothing is known yet about whether it helped. There was no placebo group.
Osel Inc Phase 2 clinical trial in CDI recurrence using MIYA-BM at 2 g BID for 42 days.
Clinical population described in trial publication.
Osel Inc Phase 2 clinical trial in CDI recurrence using MIYA-BM at 2 g BID for 42 days. The trial was withdrawn and produced no data at all. The listed reason was low enrollment rather than a safety problem, but the practical point is simple: there is no US trial evidence for this use.
Kaohsiung Medical University randomized crossover trial, currently enrolling by invitation.
Clinical population described in trial publication.
Kaohsiung Medical University randomized crossover trial, currently enrolling by invitation. This trial is still enrolling and has produced no results. The reasoning behind it comes from laboratory work only. There is no evidence that this probiotic prevents polyps or bowel cancer, and it is not a replacement for colonoscopy or the follow-up your doctor recommends.
Seki H et al., Pediatr Int 2003;45(1):86-90 (PMID 12654076). Children receiving antibiotics.
Clinical population described in trial publication.
Seki H et al. 2003 studied children taking antibiotics and reported fewer cases of antibiotic-associated diarrhea with C. butyricum MIYAIRI. It is a single study from more than twenty years ago, done in children, and it is the only human evidence for this use cited on the page. Results in children do not automatically apply to adults. The mucus-layer explanation comes from laboratory work, not from this study.